Indivior PLC (NASDAQ:INDV) Short Interest Update

Indivior PLC (NASDAQ:INDV - Get Free Report) was the recipient of a significant increase in short interest in April. As of April 15th, there was short interest totalling 201,800 shares, an increase of 15.8% from the March 31st total of 174,300 shares. Based on an average daily volume of 129,300 shares, the days-to-cover ratio is presently 1.6 days. Approximately 0.2% of the company's stock are sold short.

Wall Street Analyst Weigh In

Separately, Craig Hallum started coverage on Indivior in a research note on Wednesday, April 3rd. They set a "buy" rating and a $37.00 price objective on the stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in INDV. Chilton Investment Co. Inc. acquired a new stake in Indivior during the 4th quarter valued at $263,000. ADAR1 Capital Management LLC bought a new position in shares of Indivior in the fourth quarter valued at about $368,000. Cannon Global Investment Management LLC acquired a new stake in shares of Indivior during the 1st quarter worth about $563,000. Campbell & CO Investment Adviser LLC boosted its holdings in shares of Indivior by 2.8% during the 4th quarter. Campbell & CO Investment Adviser LLC now owns 37,948 shares of the company's stock worth $573,000 after buying an additional 1,037 shares during the period. Finally, Hsbc Holdings PLC bought a new stake in shares of Indivior during the 4th quarter worth about $649,000. 60.33% of the stock is currently owned by institutional investors.

Indivior Stock Performance

Shares of Indivior stock traded up $0.35 during trading on Monday, hitting $17.93. 165,976 shares of the stock were exchanged, compared to its average volume of 122,442. The company has a current ratio of 0.92, a quick ratio of 0.74 and a debt-to-equity ratio of 23.50. The company has a fifty day moving average price of $20.49 and a 200-day moving average price of $18.27. The stock has a market capitalization of $2.47 billion, a price-to-earnings ratio of 1,793.00 and a beta of 0.46. Indivior has a 1-year low of $14.38 and a 1-year high of $26.50.

Indivior (NASDAQ:INDV - Get Free Report) last posted its quarterly earnings results on Thursday, February 22nd. The company reported $0.43 EPS for the quarter, topping analysts' consensus estimates of $0.28 by $0.15. The business had revenue of $293.00 million during the quarter, compared to analysts' expectations of $260.00 million. Indivior had a return on equity of 842.72% and a net margin of 0.44%. As a group, equities analysts predict that Indivior will post 2.03 EPS for the current fiscal year.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.